66 related articles for article (PubMed ID: 29233743)
1. A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.
Torka P; Patel P; Tan W; Wilding G; Bhat SA; Czuczman MS; Lee KP; Deeb G; Neppalli V; Mavis C; Wallace P; Hernandez-Ilizaliturri FJ
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e51-e60. PubMed ID: 29233743
[TBL] [Abstract][Full Text] [Related]
2. Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.
Cerchione C; De Renzo A; Di Perna M; Della Pepa R; Pugliese N; Catalano L; Pane F; Picardi M
Support Care Cancer; 2017 Mar; 25(3):839-845. PubMed ID: 27812763
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
Calip GS; Moran KM; Sweiss KI; Patel PR; Wu Z; Adimadhyam S; Lee TA; Ko NY; Quigley JG; Chiu BC
Cancer; 2019 Apr; 125(7):1143-1154. PubMed ID: 30548485
[TBL] [Abstract][Full Text] [Related]
4. Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20
Munoz J; Flinn IW; Cohen JB; Sachs J; Exter B; Ranger A; Harris P; Payumo F; Nath R; Hamadani M; Westin JR; Bachanova V
Transplant Cell Ther; 2024 Feb; 30(2):241.e1-241.e8. PubMed ID: 37898374
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20
Luo C; Wu G; Huang X; Ma Y; Zhang Y; Song Q; Xie M; Sun Y; Huang Y; Huang Z; Hou Y; Xu S; Chen J; Li X
Sci Rep; 2021 Feb; 11(1):3255. PubMed ID: 33547368
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.
Salles G; Barrett M; Foà R; Maurer J; O'Brien S; Valente N; Wenger M; Maloney DG
Adv Ther; 2017 Oct; 34(10):2232-2273. PubMed ID: 28983798
[TBL] [Abstract][Full Text] [Related]
7. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
Timmerman J; Herbaux C; Ribrag V; Zelenetz AD; Houot R; Neelapu SS; Logan T; Lossos IS; Urba W; Salles G; Ramchandren R; Jacobson C; Godwin J; Carpio C; Lathers D; Liu Y; Neely J; Suryawanshi S; Koguchi Y; Levy R
Am J Hematol; 2020 May; 95(5):510-520. PubMed ID: 32052473
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.
Davies A; Berge C; Boehnke A; Dadabhoy A; Lugtenburg P; Rule S; Rummel M; McIntyre C; Smith R; Badoux X
Adv Ther; 2017 Oct; 34(10):2210-2231. PubMed ID: 28983819
[TBL] [Abstract][Full Text] [Related]
9. Rituximab as a therapeutic option for patients with advanced melanoma.
Winkler JK; Schiller M; Bender C; Enk AH; Hassel JC
Cancer Immunol Immunother; 2018 Jun; 67(6):917-924. PubMed ID: 29516155
[TBL] [Abstract][Full Text] [Related]
10. Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab.
Morcos PN; Moss J; Austin R; Hiemeyer F; Zinzani PL; Beckert V; Mongay Soler L; Childs BH; Garmann D
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1666-1686. PubMed ID: 37389853
[TBL] [Abstract][Full Text] [Related]
11. Conjunctival lymphoma.
Li JJ; Chen W; Sadeghi N
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31296640
[No Abstract] [Full Text] [Related]
12. Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy.
Bommier C; Zucca E; Chevret S; Conconi A; Nowakowski G; Maurer MJ; Cerhan JR; Thieblemont C; Lambert J
Blood; 2024 Feb; 143(5):422-428. PubMed ID: 37801707
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and predictors of infusion-related reactions to rituximab in patients with B-cell non-Hodgkin lymphoma.
Faqeer N; Alrabie R; Al-Haddadin R; Ma'koseh M
J Chemother; 2023 Oct; ():1-8. PubMed ID: 37860948
[TBL] [Abstract][Full Text] [Related]
14.
Frank MJ; Reagan PM; Bartlett NL; Gordon LI; Friedberg JW; Czerwinski DK; Long SR; Hoppe RT; Janssen R; Candia AF; Coffman RL; Levy R
Cancer Discov; 2018 Oct; 8(10):1258-1269. PubMed ID: 30154192
[TBL] [Abstract][Full Text] [Related]
15. Reducing chemotherapy dose intensity by 25% and adding rituximab improves survival in pediatric mature B-cell non-Hodgkin lymphoma in LMIC setting.
Radhakrishnan V; Kritthivasan V; Kothandan BT; Srinivasan P; Das G; Ramamurthy J
Pediatr Blood Cancer; 2023 Dec; 70(12):e30694. PubMed ID: 37740580
[TBL] [Abstract][Full Text] [Related]
16. Novel agents for B-cell non-Hodgkin lymphoma: science and the promise.
Tay K; Dunleavy K; Wilson WH
Blood Rev; 2010 Mar; 24(2):69-82. PubMed ID: 20153097
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.
Melhem M; Delor I; Pérez-Ruixo JJ; Harrold J; Chow A; Wu L; Jacqmin P
Br J Clin Pharmacol; 2018 May; 84(5):911-925. PubMed ID: 29318653
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting.
Tanaka I; Kawada K; Morise M; Hase T; Hayashi H; Sokai A; Fukatsu A; Kondo M; Nomura F; Hasegawa Y
Cancer Chemother Pharmacol; 2018 Feb; 81(2):339-345. PubMed ID: 29234921
[TBL] [Abstract][Full Text] [Related]
19. Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?
Leleu X; Gay F; Flament A; Allcott K; Delforge M
Ann Hematol; 2018 Mar; 97(3):387-400. PubMed ID: 29282494
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.
Zhu J; Huang H; Chen H; Zhang X; Li Z; Wu D; Zhou D; Song Y; Hu Y; Liang Y; Ren H; Huang H; Li N; Chen H; Hu J; Li J; Meng R; Wu J; Yu D; Huang X
Transfusion; 2018 Jan; 58(1):81-87. PubMed ID: 29238988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]